2Rotter T,Koch R,Kugler J,et al.Clinical pathways:effects on professional practice,patient outcomes,length of stay and hospital costs[J].Cochrane Database Syst Rev,2007,3:6632.
4WOLF P, ABBOTT RD, KANNEL WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study [ J ]. Stroke, 1991, 22(8) : 983 -988.
5CONNOLLY SJ, EZEKOWITZ MD, YUSUF S, et al. Dablgat- ran versus warfarin in patients with atrial fibrillation[ J]. N Engl JMed, 2009, 361(12): 1139 -1151.
6PATEL MR, MAHAFFEY KW, GARG J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [ J ]. N Engl J Med, 2011, 365(10): 883-891.
7WHO. Choosing Interventions that arc Cost Effective ( WHO- CHOICE) , Threshold values for intervention cost-effectiveness by Region[ EB/OL]. 2010[2016 -01 -29]. http://www, who. int/choice/costs/CER_levels/en/.
8KREJCZY M, HARENBERG J, MARX S, et al. Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and aplxaban in patients with non-valvular atrial fibrillation across countries[J]. J Thromb Thrombolysis, 2014, 37 (4) : 507 - 523.
9WISLOFFT, HAGEN G, KLEMPM. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke pre- vention in atrial fibrillation( J ]. Pharmacoeconomics, 2014, 32 (6) : 601 -612.
10CHANG CH, YANG YHK, CHEN JH, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan [ J] Thrombosis Res, 2014, 133(5) : 782 -789.
